In this study, patients with stage II-IIIB resectable EGFR-mutant NSCLC were randomized to receive neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone prior to surgical resection; following surgery, systemic therapy-eligible patients (over 90%) were offered adjuvant osimertinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.